Grants for Unrestricted - Science and Technology

Bipartisan Infrastructure Law (BIL) - Clean Fuels Products Shot: Supporting Carbon Utilization Products via Electrochemical Conversion and Refinery and Petrochemical Facilities Retrofitting The Office of Fossil Energy and Carbon Management (FECM) in collaboration with the National Energy Technology Laboratory (NETL) is issuing this Funding Opportunity Announcement (FOA). Awards made under this FOA will be funded, in whole or in part, with funds appropriated by the Infrastructure Investment and Jobs Act, more commonly known as the Bipartisan Infrastructure Law (BIL). The activities to be funded under this Funding Opportunity Announcement support BIL Section 40302. Research and Development funded under this Funding Opportunity Announcement will support the Departments Clean Fuels Products Shots initiative, which was established to support the national goal of achieving net-zero emissions by 2050 by developing the sustainable feedstocks and conversion technologies necessary to produce crucial fuels, materials, and carbon-based products that are better for the environment than current petroleum-derived components. It aims to meet projected 2050 net-zero emissions demands for 100 percent of aviation fuel; 50 percent of maritime, rail, and off-road fuel; and 50 percent of carbon-based chemicals by using sustainable carbon resources. Modification 000001: The purpose of this modification is to update wording within the Topic Area descriptions to clarify the Funding Opportunity Announcement does not restrict conversion of carbon oxides, change instances of "CO2" to "carbon" throughout the Funding Opportunity Announcement, and clarify the medium-term test requirement for Topic Area 1.

The "Carbon Management" grant, offered by the Department of Energy, provides $78.4 million in funding for U.S. organizations to develop and test technologies for capturing, removing, converting, and storing carbon to combat climate change, with applications due by October 14, 2024.

The FY24 ALSRP Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in Amyotrophic Lateral Sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients.Research may include, but is not limited to:Target engagement biomarkers.Objective pharmacodynamic biomarkers to measure the biological effect of an investigational therapeutic.Predictive/cohort-selective biomarkers that indicate whether a specific therapy will be effective in an individual patient or patient subgroup.Diagnostic, prognostic, or disease progressionValidate clinician-, observer-, patient-reported and/or performance outcomes to better support clinical trial success metrics.Define ALS subtypes using patient-based resources to link biosamples and/or digital data elements to rigorous molecular and clinical data.Realize improved strategies that better measure disease progression for people living with ALS.Augment biospecimens, outcome, or digital health data to an on-going clinical trial.Correlate clinical-trial related data (e.g., biosample, imaging, digital health data) with clinical outcomes or responses to therapies.Use of existing well-characterized and highly curated clinical resources is encouraged. Examples of patient-based ALS resources include ongoing or completed clinical trial datasets, biorepositories of clinical specimens, registries (e.g., Centers for Disease Control and Prevention National ALS Registry and/or Biorepository; https://www.cdc.gov/als/Default.html), large omics datasets, patient-report outcomes, digital biomarker datasets, and databases of clinical data and/or metadata. Active-duty military and/or Veteran patient populations or resources should be considered. A list of suitable resources can be found on the ALSRP web page (https://cdmrp.health.mil/alsrp/resources/ALSRPresources). Other resources may be used, provided they have an adequate description of repository parameters and mechanisms for broad access.

This initiative seeks input from researchers and industry stakeholders on innovative technologies to replace traditional heating systems in refineries and petrochemical plants with efficient nuclear heat solutions, aiming to significantly reduce emissions and improve process efficiency.

This grant provides funding for organizations in the Colorado Plateau or Desert Southwest regions to conduct bat surveys and conservation efforts at Fort Carson and the Piñon Canyon Maneuver Site, focusing on protecting species like the tricolored bat from threats such as white-nose syndrome.

This funding opportunity supports collaborative research partnerships among academic institutions, nonprofits, and small businesses in the U.S. to advance scientific innovation and address critical health challenges, particularly for underserved populations.

This funding opportunity is designed to support researchers and companies developing advanced technologies for converting carbon dioxide into useful products, focusing on biological, catalytic, and mineralization methods.

This grant provides funding for research and development in advanced multi-spectral sensing technologies, targeting a wide range of organizations including small businesses and research institutions, to enhance military intelligence and operational capabilities.

This grant provides funding for research and technology development in weather and atmospheric dynamics, aimed at advancing our understanding of Earth and space sciences.

This funding opportunity is designed for national laboratories to collaborate with industry stakeholders in the chemicals, concrete, and metals sectors to develop and implement strategies that accelerate the commercialization of technologies aimed at reducing industrial carbon emissions.

This funding opportunity is designed for research organizations affiliated with the Colorado Plateau Cooperative Ecosystem Studies Unit to study and improve land management practices that reduce wildfire risks and restore ecosystems in the southwestern United States.

The grant titled "ROSES 2024: C.27 Lucy in the L4 Trojans Participating Scientist Program" is a funding opportunity by NASA's Science Mission Directorate for research and technology in space and Earth sciences, with a specific focus on the Lucy in the L4 Trojans project, and it invites proposals from various types of organizations, both domestic and foreign.

This grant supports researchers in mathematical and statistical sciences to develop innovative tools and theories that address challenges in computation and big data, while fostering collaboration and training for early-career scientists.

This program provides funding for educational and research initiatives in Earth sciences, targeting undergraduate students, early-career researchers, and faculty to promote diversity and broaden participation in the field.

This grant provides funding for organizations specializing in cultural resource management to support archaeological surveys and compliance with preservation laws at Joint Base Langley-Eustis in Virginia.

The DoD Kidney Cancer, Translational Research Partnership Award is a funding opportunity designed to support collaborative research projects between clinicians and scientists, with the aim of accelerating the development and application of innovative ideas in kidney cancer treatment and care, particularly those relevant to active-duty Service Members, Veterans, and the American public.

30 MAY 2024: The purpose of this amendment is to provide the finalized ISO and to provide the Administrative and National Security Form. 17 MAY 2024: The purpose of this amendment is to provide an updated Draft ISO, and the cost proposal worksheets. 22 APRIL 2024: The purpose of this amendment is to extend the Full Proposal due date to August 20, 2024, at 5:00pm, ET. 10 APRIL 2024: The Advanced Research Projects Agency for Health (ARPA-H) posts this funding opportunity in support of the Personalized Regenerative Immunocompetent Nanotechnology Tissue (PRINT) Program. ARPA-H anticipates multiple awards and award types will result from this announcement. Interested parties are invited to review the attached PRINT Innovative Solutions Opening (ISO) ARPA-H-SOL-24-101. 27 MARCH 2024: The Advanced Research Projects Agency for Health (ARPA-H) posts this funding opportunity in support of the Personalized Regenerative Immunocompetent Nanotechnology Tissue (PRINT) Program. ARPA-H anticipates multiple awards and award types will result from this announcement. ARPA-H will host a Proposers Day on May 07, 2024. The event will allow for both in-person and virtual participation and is intended to facilitate teaming and foster a greater understanding of the PRINT Program. The closing date for registration is April 30, 2024, 1:00 PM ET. In-person attendance is first-come, first-served or when capacity is reached. After reviewing the attached Proposers Day information, interested parties are encouraged to register at the link below. https://arpa-h.gov/research-and-funding/programs/print Solution Summary Due Date and Time: May 28, 2024, 9:00 AM ET Proposals will be by invitation only. Proposal Due Date and Time: August 20, 2024, 9:00 AM ET For more information about ARPA-H, please visit https://arpa-h.gov

This initiative seeks innovative partnership models from academic institutions to enhance collaboration with the U.S. Army on scientific and technological research, including both open and classified projects.

This program provides funding to interdisciplinary teams developing automated tools to ensure the accuracy and reliability of AI models used in healthcare, addressing performance degradation and enhancing patient safety.

The Patient-Centered Outcomes and Survivorship Award supports high-risk, high-reward research studies that span the spectrum of behavioral health science, survivorship, health outcomes and comparative effectiveness research, including quality of life, symptom and side effect management, resilience, co-morbid conditions, and examining the physical, psychological, social, and economic effects of lung cancer among patients and their families.The overall intent of the FY24 LCRP Patient-Centered Outcomes and Survivorship Award is to promote evidence-based and patient-centered approaches to improve health and lung cancer related outcomes and enhance the patient experience in defined populations. Research studies may include, but are not limited to:Studies to examine and improve quality of life, decision-making, and symptom and side effect management (e.g., toxicity of treatment, palliative/supportive care, psychological distress and anxiety).Studies to investigate the impact of prevention, diagnostics, treatment, or health care delivery approaches on health outcomes.Studies to assess the relationship(s) between behavioral, cognitive, and/or social functioning in relation to lung cancer detection, initiation, progression, treatment, and rehabilitation.Studies into the psychological health and well-being of those affected by lung cancer (e.g., patients, family members).Development and testing for efficacy of lifestyle interventions and symptom management approaches to minimize disease risk and maximize quality of life.Key aspects of this award mechanism are:Impact: The Patient-Centered Outcomes and Survivorship Award is intended to support research that demonstrates the potential to have a major impact on patient outcomes. Research should challenge paradigms with respect to impact on patient care and outcomes. Proposed projects may include translational or clinical research, including pilot clinical trials. Impactful research will accelerate the movement of promising ideas into clinical applications, generate knowledge to improve clinical guidelines, or significantly advance behavioral, cognitive, and/or social functioning related to the target population.Study Design: Applications should clearly articulate the chosen design of the study. Basic studies should demonstrate research strategy, feasibility, and how the study relates to the human experience with lung cancer. Studies entailing retrospective or prospective recruitment should define the type of architecture of the study (e.g., descriptive, correlational, field experimental, meta-analyses). Study populations should be defined. The rationale should support the chosen study design with statistical evaluation to back the design. Questionnaires should be described in sufficient detail to justify interpretation of potential results.Preliminary Data: The Patient-Centered Outcomes and Survivorship Award requires preliminary data for all studies that propose the active (prospective) recruitment of human subjects. Studies not proposing active recruitment of human subjects are not required to present preliminary data but should be supported by sound reasoning and relevant literature.Patient Advocate Participation: Applications to the Patient-Centered Outcomes and Survivorship Award funding opportunity are encouraged to include a patient advocate. As part of the research team, the patient advocate would assist in the development of the research question, project design, oversight, recruitment, and evaluation, as well as other significant aspects of the proposed project. The patient advocate will be a person with a history of lung cancer diagnosis. As a lay representative, the patient advocate should be active in a cancer advocacy organization. Interactions with other team members should be well integrated and ongoing, not limited to attending seminars and semi-annual meetings. The role of the patient advocate should be focused on providing objective input on the research and its potential impact for individuals with or at risk for lung cancer.